Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Bioconjugate Chemistry

Volumn 27, Issue 10, 2016, Pages 2225-2238

  Nakamura, Yuko ^a   Mochida, Ai ^a   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; MEDICAL NANOTECHNOLOGY; TARGETED DRUG DELIVERY; TUMORS;

CANCER DIAGNOSIS; CONTROLLED RELEASE; DESIGN FEATURES; ENHANCED PERMEABILITY AND RETENTION EFFECT; LARGE SURFACES; LOADING CAPACITIES; NANODRUGS; SUSTAINED RELEASE; TARGETING LIGANDS; TUMOUR TISSUE;

CURING;

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; DNA VACCINE; DOCETAXEL; DOXORUBICIN; ENALAPRIL; GLYCERYL TRINITRATE; GOLD NANOROD; GROWTH FACTOR; MONOCLONAL ANTIBODY; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; TUMOR NECROSIS FACTOR; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; DRUG CARRIER;

APOPTOSIS; BLOOD VESSEL PERMEABILITY; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CAPILLARY WALL; CELL KILLING; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; EXTRACELLULAR MATRIX; EXTRAVASCULAR SPACE; HUMAN; HYPERTHERMIA; NANOMEDICINE; NANOTECHNOLOGY; NEAR INFRARED PHOTOIMMUNOTHERAPY; NEAR INFRARED SPECTROSCOPY; NEOPLASM; NONHUMAN; PARTICLE SIZE; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PHOTOTHERAPY; PHOTOTHERMAL THERAPY; RADIOIMMUNOTHERAPY; REVIEW; SOLID; SOLID TUMOR; STROMA; TISSUE PRESSURE; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR TUMOR; ANIMAL; CAPILLARY PERMEABILITY; CHEMISTRY; LEGISLATION AND JURISPRUDENCE; PROCEDURES; UNITED STATES; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NEOPLASMS; RADIOIMMUNOTHERAPY; UNITED STATES; VASODILATOR AGENTS;

EID: 84992363294     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.6b00437     Document Type: Review

References (166)

1. Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D. S., and Egorin, M. J. (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin. Cancer Res. 8, 878-84
2. Ng, K. K., Lovell, J. F., and Zheng, G. (2011) Lipoprotein-inspired nanoparticles for cancer theranostics Acc. Chem. Res. 44, 1105-13 10.1021/ar200017e
3. Patel, S., Bhirde, A. A., Rusling, J. F., Chen, X., Gutkind, J. S., and Patel, V. (2011) Nano delivers big: designing molecular missiles for cancer therapeutics Pharmaceutics 3, 34-52 10.3390/pharmaceutics3010034
4. Perche, F. and Torchilin, V. P. (2013) Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting J. Drug Delivery 2013, 705265 10.1155/2013/705265
5. Stylianopoulos, T. and Jain, R. K. (2015) Design considerations for nanotherapeutics in oncology Nanomedicine 11, 1893-907 10.1016/j.nano.2015.07.015
6. Longmire, M., Choyke, P. L., and Kobayashi, H. (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats Nanomedicine (London, U. K.) 3, 703-17 10.2217/17435889.3.5.703
7. Longmire, M. R., Ogawa, M., Choyke, P. L., and Kobayashi, H. (2011) Biologically optimized nanosized molecules and particles: more than just size Bioconjugate Chem. 22, 993-1000 10.1021/bc200111p
8. Rose, P. G. (2005) Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer Oncologist 10, 205-14 10.1634/theoncologist.10-3-205
9. McNerny, D. Q., Leroueil, P. R., and Baker, J. R. (2010) Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2, 249-59 10.1002/wnan.79
10. Matsumura, Y. and Kataoka, K. (2009) Preclinical and clinical studies of anticancer agent-incorporating polymer micelles Cancer Sci. 100, 572-9 10.1111/j.1349-7006.2009.01103.x
11. Kobayashi, H. and Brechbiel, M. W. (2003) Dendrimer-based macromolecular MRI contrast agents: characteristics and application Mol. Imaging 2, 1-10 10.1162/153535003765276237
12. Kobayashi, H. and Brechbiel, M. W. (2005) Nano-sized MRI contrast agents with dendrimer cores Adv. Drug Delivery Rev. 57, 2271-86 10.1016/j.addr.2005.09.016
13. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46, 6387-92
14. Maeda, H., Tsukigawa, K., and Fang, J. (2016) A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy-Problems, Solutions, and Prospects Microcirculation 23, 173-82 10.1111/micc.12228
15. Nishihara, H. (2014) Human pathological basis of blood vessels and stromal tissue for nanotechnology Adv. Drug Delivery Rev. 74, 19-27 10.1016/j.addr.2014.01.005
16. Armulik, A., Genove, G., and Betsholtz, C. (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises Dev. Cell 21, 193-215 10.1016/j.devcel.2011.07.001
17. Sims, D. E. (1986) The pericyte - a review Tissue Cell 18, 153-74 10.1016/0040-8166(86)90026-1
18. Yokoi, K., Kojic, M., Milosevic, M., Tanei, T., Ferrari, M., and Ziemys, A. (2014) Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment Cancer Res. 74, 4239-46 10.1158/0008-5472.CAN-13-3494
19. Inoue, S. (1989) Ultrastructure of basement membranes Int. Rev. Cytol. 117, 57-98 10.1016/S0074-7696(08)61334-0
20. Danquah, M. K., Zhang, X. A., and Mahato, R. I. (2011) Extravasation of polymeric nanomedicines across tumor vasculature Adv. Drug Delivery Rev. 63, 623-39 10.1016/j.addr.2010.11.005
21. McDonald, D. M., Thurston, G., and Baluk, P. (1999) Endothelial gaps as sites for plasma leakage in inflammation Microcirculation 6, 7-22 10.1080/713773924
22. Yurchenco, P. D. and Ruben, G. C. (1987) Basement membrane structure in situ: evidence for lateral associations in the type IV collagen network J. Cell Biol. 105, 2559-68 10.1083/jcb.105.6.2559
23. Kanapathipillai, M., Brock, A., and Ingber, D. E. (2014) Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment Adv. Drug Delivery Rev. 79-80, 107-18 10.1016/j.addr.2014.05.005
24. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., and McDonald, D. M. (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors Am. J. Pathol. 163, 1801-15 10.1016/S0002-9440(10)63540-7
25. Miao, L. and Huang, L. (2015) Exploring the tumor microenvironment with nanoparticles Cancer Treat. Res. 166, 193-226 10.1007/978-3-319-16555-4-9
26. Chan, R. C., Babbs, C. F., Vetter, R. J., and Lamar, C. H. (1984) Abnormal response of tumor vasculature to vasoactive drugs J. Natl. Cancer Inst. 72, 145-50
27. Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., and Blakey, D. C. (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 73, 2412-7 10.1158/0008-5472.CAN-12-4561
28. O'Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., and Ackland, S. P. et al. 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15, 440-9 10.1093/annonc/mdh097
29. Rabanel, J. M., Aoun, V., Elkin, I., Mokhtar, M., and Hildgen, P. (2012) Drug-loaded nanocarriers: passive targeting and crossing of biological barriers Curr. Med. Chem. 19, 3070-102 10.2174/092986712800784702
30. Thurber, G. M., Schmidt, M. M., and Wittrup, K. D. (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance Adv. Drug Delivery Rev. 60, 1421-34 10.1016/j.addr.2008.04.012
31. Marcucci, F. and Corti, A. (2012) How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs Adv. Drug Delivery Rev. 64, 53-68 10.1016/j.addr.2011.09.007
32. Fukumura, D., Duda, D. G., Munn, L. L., and Jain, R. K. (2010) Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models Microcirculation 17, 206-25 10.1111/j.1549-8719.2010.00029.x
33. Ziyad, S. and Iruela-Arispe, M. L. (2011) Molecular mechanisms of tumor angiogenesis Genes Cancer 2, 1085-96 10.1177/1947601911432334
34. Papetti, M. and Herman, I. M. (2002) Mechanisms of normal and tumor-derived angiogenesis American journal of physiology. Cell physiology 282, C947-70 10.1152/ajpcell.00389.2001
35. Konerding, M. A., Miodonski, A. J., and Lametschwandtner, A. (1995) Microvascular corrosion casting in the study of tumor vascularity: a review Scanning Microscopy 9, 1233-43 discussion 1243-4.
36. Jain, R. K. (2003) Molecular regulation of vessel maturation Nat. Med. 9, 685-93 10.1038/nm0603-685
37. Jain, R. K. (1988) Determinants of tumor blood flow: a review Cancer Res. 48, 2641-58
38. Carmeliet, P. and Jain, R. K. (2000) Angiogenesis in cancer and other diseases Nature 407, 249-57 10.1038/35025220
39. Huynh, E. and Zheng, G. (2015) Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect Nanomedicine (London, U. K.) 10, 1993-5 10.2217/nnm.15.86
40. Jain, R. K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307, 58-62 10.1126/science.1104819
41. Jain, R. K. (1987) Transport of molecules in the tumor interstitium: a review Cancer Res. 47, 3039-51
42. Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., and Zecchini, H. I. et al. 2013, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer Gut 62, 112-20 10.1136/gutjnl-2012-302529
43. Boucher, Y. and Jain, R. K. (1992) Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse Cancer Res. 52, 5110-4
44. Jain, R. K. and Stylianopoulos, T. (2010) Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7, 653-64 10.1038/nrclinonc.2010.139
45. Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., di Tomaso, E., and Jain, R. K. (2004) Pathology: cancer cells compress intratumour vessels Nature 427, 695 10.1038/427695a
46. Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., and Boucher, Y. et al. 2012, Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors Proc. Natl. Acad. Sci. U. S. A. 109, 15101-8 10.1073/pnas.1213353109
47. Lu, D., Wientjes, M. G., Lu, Z., and Au, J. L. (2007) Tumor priming enhances delivery and efficacy of nanomedicines J. Pharmacol. Exp. Ther. 322, 80-8 10.1124/jpet.107.121632
48. Jain, R. K., Martin, J. D., and Stylianopoulos, T. (2014) The role of mechanical forces in tumor growth and therapy Annu. Rev. Biomed. Eng. 16, 321-46 10.1146/annurev-bioeng-071813-105259
49. Khawar, I. A., Kim, J. H., and Kuh, H. J. (2015) Improving drug delivery to solid tumors: priming the tumor microenvironment J. Controlled Release 201, 78-89 10.1016/j.jconrel.2014.12.018
50. Egeblad, M., Rasch, M. G., and Weaver, V. M. (2010) Dynamic interplay between the collagen scaffold and tumor evolution Curr. Opin. Cell Biol. 22, 697-706 10.1016/j.ceb.2010.08.015
51. Lu, P., Weaver, V. M., and Werb, Z. (2012) The extracellular matrix: a dynamic niche in cancer progression J. Cell Biol. 196, 395-406 10.1083/jcb.201102147
52. Maquart, F. X., Bellon, G., Pasco, S., and Monboisse, J. C. (2005) Matrikines in the regulation of extracellular matrix degradation Biochimie 87, 353-60 10.1016/j.biochi.2004.10.006
53. Gilkes, D. M., Semenza, G. L., and Wirtz, D. (2014) Hypoxia and the extracellular matrix: drivers of tumour metastasis Nat. Rev. Cancer 14, 430-9 10.1038/nrc3726
54. Frantz, C., Stewart, K. M., and Weaver, V. M. (2010) The extracellular matrix at a glance J. Cell Sci. 123, 4195-200 10.1242/jcs.023820
55. Egeblad, M., Nakasone, E. S., and Werb, Z. (2010) Tumors as organs: complex tissues that interface with the entire organism Dev. Cell 18, 884-901 10.1016/j.devcel.2010.05.012
56. Loeffler, M., Kruger, J. A., Niethammer, A. G., and Reisfeld, R. A. (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake J. Clin. Invest. 116, 1955-62 10.1172/JCI26532
57. Venditto, V. J. and Szoka, F. C., Jr. (2013) Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Delivery Rev. 65, 80-8 10.1016/j.addr.2012.09.038
58. Valencia, P. M., Farokhzad, O. C., Karnik, R., and Langer, R. (2012) Microfluidic technologies for accelerating the clinical translation of nanoparticles Nat. Nanotechnol. 7, 623-9 10.1038/nnano.2012.168
59. Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., and Prina-Mello, A. (2016) Nanomedicine applied to translational oncology: A future perspective on cancer treatment Nanomedicine 12, 81-103 10.1016/j.nano.2015.08.006
60. Vance, M. E., Kuiken, T., Vejerano, E. P., McGinnis, S. P., Hochella, M. F., Jr., Rejeski, D., and Hull, M. S. (2015) Nanotechnology in the real world: Redeveloping the nanomaterial consumer products inventory Beilstein J. Nanotechnol. 6, 1769-80 10.3762/bjnano.6.181
61. Wacker, M. G., Proykova, A., and Santos, G. M. (2016) Dealing with nanosafety around the globe-Regulation vs. innovation Int. J. Pharm. 509, 95-106 10.1016/j.ijpharm.2016.05.015
62. Bawa, R. (2013) Bio-Nanotechnology: A Revolution in Food, Biomedical and Health Science, 2012/10/09 ed., Wiley-Blackwell.
63. Tinkle, S., McNeil, S. E., Muhlebach, S., Bawa, R., Borchard, G., Barenholz, Y. C., Tamarkin, L., and Desai, N. (2014) Nanomedicines: addressing the scientific and regulatory gap Ann. N. Y. Acad. Sci. 1313, 35-56 10.1111/nyas.12403
64. Draft Guidance for Industry. (2011) Considering whether and FDA regulated product involves the application of nanotechnology 2011. Available from: http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm.
65. Commision Recommendation of 18 October 2011 on the definition of nanomaterial. nanomaterial. (2014) Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:275:0038:0040:EN:PDF.
66. Scientific Committee on Emerging and Newly Identified Health Risks. Scientific basis for the definition of the term ″nanomaterial″. (2010) Available from: http://ec.europa.eu/health/scientific-committees/emerging/docs/scenihr-o-030.pdf.
67. U.S. Food and Drug Administration. ((2007) Nanotechnology: a report of the US Food and Drug Administration, Nanotechnology Task Force. Available from: http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm2006659.htm.
68. Hamburg, M. A. (2012) Science and regulation. FDA's approach to regulation of products of nanotechnology Science 336, 299-300 10.1126/science.1205441
69. Lammers, T., Kiessling, F., Hennink, W. E., and Storm, G. (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Controlled Release 161, 175-87 10.1016/j.jconrel.2011.09.063
70. Kobayashi, H., Turkbey, B., Watanabe, R., and Choyke, P. L. (2014) Cancer drug delivery: considerations in the rational design of nanosized bioconjugates Bioconjugate Chem. 25, 2093-100 10.1021/bc500481x
71. Suzuki, M., Hori, K., Abe, I., Saito, S., and Sato, H. (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II J. Natl. Cancer Inst. 67, 663-9
72. Nagamitsu, A., Greish, K., and Maeda, H. (2009) Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors Jpn. J. Clin. Oncol. 39, 756-66 10.1093/jjco/hyp074
73. Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Despres, J. P., and Fullerton, H. J. et al. 2016, Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association Circulation 133, e38-e360 10.1161/CIR.0000000000000350
74. Jang, S. H., Wientjes, M. G., and Au, J. L. (2001) Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule J. Pharmacol. Exp. Ther. 296, 1035-42
75. Ji, R. C. (2005) Characteristics of lymphatic endothelial cells in physiological and pathological conditions Histology and Histopathology 20, 155-75
76. Turini, D., Nicita, G., Fiorelli, C., Selli, C., and Villari, N. (1976) Selective transcatheter arterial embolization of renal carcinoma: an original technique Journal of Urology 116, 419-21
77. Georgi, M. and Freitag, B. (1980) [Pharmaco-angiography of liver tumours (author's transl)] Rofo 132, 287-93 10.1055/s-2008-1056566
78. Li, C. J., Miyamoto, Y., Kojima, Y., and Maeda, H. (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure Br. J. Cancer 67, 975-80 10.1038/bjc.1993.179
79. Maeda, H. (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond J. Controlled Release 164, 138-44 10.1016/j.jconrel.2012.04.038
80. Maeda, H. (2012) Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting Proc. Jpn. Acad., Ser. B 88, 53-71 10.2183/pjab.88.53
81. Maeda, H. (2014) Research spotlight: emergence of EPR effect theory and development of clinical applications for cancer therapy Ther. Delivery 5, 627-30 10.4155/tde.14.36
82. Maeda, H., Bharate, G. Y., and Daruwalla, J. (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71, 409-19 10.1016/j.ejpb.2008.11.010
83. Miyamoto, Y. and Maeda, H. (1991) Enhancement by verapamil of neocarzinostatin action on multidrug-resistant Chinese hamster ovary cells: possible release of nonprotein chromophore in cells Jpn. J. Cancer Res. 82, 351-6 10.1111/j.1349-7006.1991.tb01853.x
84. Seki, T., Fang, J., and Maeda, H. (2009) Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application Cancer Sci. 100, 2426-30 10.1111/j.1349-7006.2009.01323.x
85. Fang, J., Qin, H., Nakamura, H., Tsukigawa, K., Shin, T., and Maeda, H. (2012) Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors Cancer Sci. 103, 535-41 10.1111/j.1349-7006.2011.02178.x
86. Yin, H., Fang, J., Liao, L., Nakamura, H., and Maeda, H. (2014) Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease J. Controlled Release 187, 14-21 10.1016/j.jconrel.2014.05.018
87. Yasuda, H. (2008) Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer Nitric Oxide 19, 205-16 10.1016/j.niox.2008.04.026
88. Yasuda, H., Yamaya, M., Nakayama, K., Sasaki, T., Ebihara, S., Kanda, A., Asada, M., Inoue, D., Suzuki, T., and Okazaki, T. et al. 2006, Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer J. Clin. Oncol. 24, 688-94 10.1200/JCO.2005.04.0436
89. Del Rosso, M., Fibbi, G., Pucci, M., Margheri, F., and Serrati, S. (2008) The plasminogen activation system in inflammation Front. Biosci., Landmark Ed. 13, 4667-86 10.2741/3032
90. Maeda, H., Wu, J., Okamoto, T., Maruo, K., and Akaike, T. (1999) Kallikrein-kinin in infection and cancer Immunopharmacology 43, 115-28 10.1016/S0162-3109(99)00104-6
91. Kou, R., Greif, D., and Michel, T. (2002) Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A J. Biol. Chem. 277, 29669-73 10.1074/jbc.M204519200
92. Wu, J., Akaike, T., and Maeda, H. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger Cancer Res. 58, 159-65
93. Reichman, H. R., Farrell, C. L., and Del Maestro, R. F. (1986) Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model J. Neurosurg. 65, 233-7 10.3171/jns.1986.65.2.0233
94. Chand, N. and Eyre, P. (1977) Bradykinin relaxes contracted airways through prostaglandin production J. Pharm. Pharmacol. 29, 387-8 10.1111/j.2042-7158.1977.tb11349.x
95. Furuta, I., Yamada, H., Sagawa, T., and Fujimoto, S. (2000) Effects of inflammatory cytokines on prostaglandin E(2) production from human amnion cells cultured in serum-free condition Gynecol. Obstet. Invest. 49, 93-7 10.1159/000010222
96. Tanaka, S., Akaike, T., Wu, J., Fang, J., Sawa, T., Ogawa, M., Beppu, T., and Maeda, H. (2003) Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium J. Drug Targeting 11, 45-52 10.1080/1061186031000086072
97. Ansiaux, R., Baudelet, C., Cron, G. O., Segers, J., Dessy, C., Martinive, P., De Wever, J., Verrax, J., Wauthier, V., and Beghein, N. et al. 2006, Botulinum toxin potentiates cancer radiotherapy and chemotherapy Clin. Cancer Res. 12, 1276-83
98. Theek, B., Baues, M., Ojha, T., Mockel, D., Veettil, S. K., Steitz, J., van Bloois, L., Storm, G., Kiessling, F., and Lammers, T. (2016) Sonoporation enhances liposome accumulation and penetration in tumors with low EPR J. Controlled Release 231, 77 10.1016/j.jconrel.2016.02.021
99. Ho, Y. J., Chang, Y. C., and Yeh, C. K. (2016) Improving Nanoparticle Penetration in Tumors by Vascular Disruption with Acoustic Droplet Vaporization Theranostics 6, 392-403 10.7150/thno.13727
100. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339, 58-61 10.1038/339058a0
101. Chen, W., Tang, T., Eastham-Anderson, J., Dunlap, D., Alicke, B., Nannini, M., Gould, S., Yauch, R., Modrusan, Z., and DuPree, K. J. et al. 2011, Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells Proc. Natl. Acad. Sci. U. S. A. 108, 9589-94 10.1073/pnas.1017945108
102. Kerbel, R. S. (2008) Tumor angiogenesis N. Engl. J. Med. 358, 2039-49 10.1056/NEJMra0706596
103. Stan, R. V., Tse, D., Deharvengt, S. J., Smits, N. C., Xu, Y., Luciano, M. R., McGarry, C. L., Buitendijk, M., Nemani, K. V., and Elgueta, R. et al. 2012, The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition Dev. Cell 23, 1203-18 10.1016/j.devcel.2012.11.003
104. Monsky, W. L., Fukumura, D., Gohongi, T., Ancukiewcz, M., Weich, H. A., Torchilin, V. P., Yuan, F., and Jain, R. K. (1999) Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor Cancer Res. 59, 4129-35
105. Helson, L., Green, S., Carswell, E., and Old, L. J. (1975) Effect of tumour necrosis factor on cultured human melanoma cells Nature 258, 731-2 10.1038/258731a0
106. Eggermont, A. M., Schraffordt Koops, H., Lienard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., and Lejeune, F. J. (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial J. Clin. Oncol. 14, 2653-65
107. Eggermont, A. M., van Geel, A. N., de Wilt, J. H., and ten Hagen, T. L. (2003) The role of isolated limb perfusion for melanoma confined to the extremities Surg. Clin. North Am. 83, 371-84 ix. 10.1016/S0039-6109(02)00095-6
108. Fraker, D. L., Alexander, H. R., Andrich, M., and Rosenberg, S. A. (1996) Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study J. Clin. Oncol. 14, 479-89
109. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J. Clin. Oncol. 10, 52-60
110. Kong, G., Braun, R. D., and Dewhirst, M. W. (2000) Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size Cancer Res. 60, 4440-5
111. Li, L., ten Hagen, T. L., Bolkestein, M., Gasselhuber, A., Yatvin, J., van Rhoon, G. C., Eggermont, A. M., Haemmerich, D., and Koning, G. A. (2013) Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia J. Controlled Release 167, 130-7 10.1016/j.jconrel.2013.01.026
112. Liu, P., Zhang, A., Xu, Y., and Xu, L. X. (2005) Study of non-uniform nanoparticle liposome extravasation in tumour Int. J. Hyperthermia 21, 259-70 10.1080/02656730500068643
113. Ranjan, A., Jacobs, G. C., Woods, D. L., Negussie, A. H., Partanen, A., Yarmolenko, P. S., Gacchina, C. E., Sharma, K. V., Frenkel, V., and Wood, B. J. et al. 2012, Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model J. Controlled Release 158, 487-94 10.1016/j.jconrel.2011.12.011
114. Dromi, S., Frenkel, V., Luk, A., Traughber, B., Angstadt, M., Bur, M., Poff, J., Xie, J., Libutti, S. K., and Li, K. C. et al. 2007, Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect Clin. Cancer Res. 13, 2722-7 10.1158/1078-0432.CCR-06-2443
115. Frenkel, V. (2008) Ultrasound mediated delivery of drugs and genes to solid tumors Adv. Drug Delivery Rev. 60, 1193-208 10.1016/j.addr.2008.03.007
116. Deckers, R. and Moonen, C. T. (2010) Ultrasound triggered, image guided, local drug delivery J. Controlled Release 148, 25-33 10.1016/j.jconrel.2010.07.117
117. Ferrara, K. W. (2008) Driving delivery vehicles with ultrasound Adv. Drug Delivery Rev. 60, 1097-102 10.1016/j.addr.2008.03.002
118. Fang, J., Nakamura, H., and Maeda, H. (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Delivery Rev. 63, 136-51 10.1016/j.addr.2010.04.009
119. Hicks, K. O., Pruijn, F. B., Secomb, T. W., Hay, M. P., Hsu, R., Brown, J. M., Denny, W. A., Dewhirst, M. W., and Wilson, W. R. (2006) Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs J. Natl. Cancer Inst 98, 1118-28 10.1093/jnci/djj306
120. Goel, S., Wong, A. H., and Jain, R. K. (2012) Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease Cold Spring Harbor Perspect. Med. 2, a006486 10.1101/cshperspect.a006486
121. Turley, R. S., Fontanella, A. N., Padussis, J. C., Toshimitsu, H., Tokuhisa, Y., Cho, E. H., Hanna, G., Beasley, G. M., Augustine, C. K., and Dewhirst, M. W. et al. 2012, Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma Clin. Cancer Res. 18, 3328-39 10.1158/1078-0432.CCR-11-3000
122. Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., and van Oosterom, A. T. (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 Br. J. Cancer 88, 1979-86 10.1038/sj.bjc.6601005
123. Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popovic, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., and Jain, R. K. (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner Nat. Nanotechnol. 7, 383-8 10.1038/nnano.2012.45
124. Jain, R. K. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat. Med. 7, 987-9 10.1038/nm0901-987
125. Sriraman, S. K., Aryasomayajula, B., and Torchilin, V. P. (2014) Barriers to drug delivery in solid tumors Tissue barriers 2, e29528 10.4161/tisb.29528
126. Taghian, A. G., Abi-Raad, R., Assaad, S. I., Casty, A., Ancukiewicz, M., Yeh, E., Molokhia, P., Attia, K., Sullivan, T., and Kuter, I. et al. 2005, Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications J. Clin. Oncol. 23, 1951-61 10.1200/JCO.2005.08.119
127. Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., and Jain, R. K. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 64, 3731-6 10.1158/0008-5472.CAN-04-0074
128. Vlahovic, G., Rabbani, Z. N., Herndon, J. E., 2nd, Dewhirst, M. W., and Vujaskovic, Z. (2006) Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation Br. J. Cancer 95, 1013-9 10.1038/sj.bjc.6603366
129. Dickson, P. V., Hamner, J. B., Sims, T. L., Fraga, C. H., Ng, C. Y., Rajasekeran, S., Hagedorn, N. L., McCarville, M. B., Stewart, C. F., and Davidoff, A. M. (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clin. Cancer Res. 13, 3942-50 10.1158/1078-0432.CCR-07-0278
130. Ley, C. D., Horsman, M. R., and Kristjansen, P. E. (2007) Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure Neoplasia 9, 108-12 10.1593/neo.06733
131. Skliarenko, J. V., Lunt, S. J., Gordon, M. L., Vitkin, A., Milosevic, M., and Hill, R. P. (2006) Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors Cancer Res. 66, 2074-80 10.1158/0008-5472.CAN-05-2046
132. Brown, E., McKee, T., diTomaso, E., Pluen, A., Seed, B., Boucher, Y., and Jain, R. K. (2003) Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation Nat. Med. 9, 796-800 10.1038/nm879
133. Goodman, T. T., Olive, P. L., and Pun, S. H. (2007) Increased nanoparticle penetration in collagenase-treated multicellular spheroids Int. J. Nanomed. 2, 265-74
134. Magzoub, M., Jin, S., and Verkman, A. S. (2007) Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin FASEB J. 22, 276-84 10.1096/fj.07-9150com
135. Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., and Jain, R. K. (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors Cancer Res. 60, 2497-503
136. Eikenes, L., Tufto, I., Schnell, E. A., Bjorkoy, A., and De Lange Davies, C. (2010) Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts Anticancer Res. 30, 359-68
137. Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., and Xu, L. (2012) TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma Proc. Natl. Acad. Sci. U. S. A. 109, 16618-23 10.1073/pnas.1117610109
138. Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., and Adstamongkonkul, P. et al. 2013, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels Nat. Commun. 4, 2516 10.1038/ncomms3516
139. Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., and Jain, R. K. (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors Proc. Natl. Acad. Sci. U. S. A. 108, 2909-14 10.1073/pnas.1018892108
140. Tredan, O., Galmarini, C. M., Patel, K., and Tannock, I. F. (2007) Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst 99, 1441-54 10.1093/jnci/djm135
141. Kizaka-Kondoh, S., Inoue, M., Harada, H., and Hiraoka, M. (2003) Tumor hypoxia: a target for selective cancer therapy Cancer Sci. 94, 1021-8 10.1111/j.1349-7006.2003.tb01395.x
142. Divan, A., Lawry, J., Dunsmore, I. R., Parsons, M. A., and Royds, J. A. (2001) p53 and p21waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas Cancer Res. 61, 3157-63
143. Grantab, R., Sivananthan, S., and Tannock, I. F. (2006) The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells Cancer Res. 66, 1033-9 10.1158/0008-5472.CAN-05-3077
144. Griffon-Etienne, G., Boucher, Y., Brekken, C., Suit, H. D., and Jain, R. K. (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications Cancer Res. 59, 3776-82
145. Lammers, T., Peschke, P., Kuhnlein, R., Subr, V., Ulbrich, K., Debus, J., Huber, P., Hennink, W., and Storm, G. (2007) Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems J. Controlled Release 117, 333-41 10.1016/j.jconrel.2006.10.032
146. Kobayashi, H., Reijnders, K., English, S., Yordanov, A. T., Milenic, D. E., Sowers, A. L., Citrin, D., Krishna, M. C., Waldmann, T. A., and Mitchell, J. B. et al. 2004, Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation Clin. Cancer Res. 10, 7712-20 10.1158/1078-0432.CCR-04-1175
147. Chen, B., Pogue, B. W., Luna, J. M., Hardman, R. L., Hoopes, P. J., and Hasan, T. (2006) Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications Clin. Cancer Res. 12, 917-23 10.1158/1078-0432.CCR-05-1673
148. Gil, M., Bieniasz, M., Seshadri, M., Fisher, D., Ciesielski, M. J., Chen, Y., Pandey, R. K., and Kozbor, D. (2011) Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice Br. J. Cancer 105, 1512-21 10.1038/bjc.2011.429
149. Snyder, J. W., Greco, W. R., Bellnier, D. A., Vaughan, L., and Henderson, B. W. (2003) Photodynamic therapy: a means to enhanced drug delivery to tumors Cancer Res. 63, 8126-31
150. Dubreta, K., Ivankovic, S., Lovrencic-Huzjan, A., Bosnar-Puretic, M., Stojkovic, R., and Jurin, M. (2009) The characterization of blood flow changes in mouse tumor during Photofrin-based photodynamic therapy by using the color Doppler ultrasonography Oncol. Rep. 22, 1253-7 10.3892/or-00000562
151. Wang, K. K., Cottrell, W. J., Mitra, S., Oseroff, A. R., and Foster, T. H. (2009) Simulations of measured photobleaching kinetics in human basal cell carcinomas suggest blood flow reductions during ALA-PDT Lasers Surg. Med. 41, 686-96 10.1002/lsm.20847
152. Gormley, A. J., Larson, N., Sadekar, S., Robinson, R., Ray, A., and Ghandehari, H. (2012) Guided Delivery of Polymer Therapeutics Using Plasmonic Photothermal Therapy Nano Today 7, 158-167 10.1016/j.nantod.2012.04.002
153. Clarke, K., Lee, F. T., Brechbiel, M. W., Smyth, F. E., Old, L. J., and Scott, A. M. (2000) Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy Clin. Cancer Res. 6, 3621-8
154. DeNardo, S. J., Kukis, D. L., Kroger, L. A., O'Donnell, R. T., Lamborn, K. R., Miers, L. A., DeNardo, D. G., Meares, C. F., and DeNardo, G. L. (1997) Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts Proc. Natl. Acad. Sci. U. S. A. 94, 4000-4 10.1073/pnas.94.8.4000
155. Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L. T., Choyke, P. L., and Kobayashi, H. (2011) Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules Nat. Med. 17, 1685-91 10.1038/nm.2554
156. Mitsunaga, M., Nakajima, T., Sano, K., Choyke, P. L., and Kobayashi, H. (2012) Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate Bioconjugate Chem. 23, 604-9 10.1021/bc200648m
157. Sato, K., Watanabe, R., Hanaoka, H., Harada, T., Nakajima, T., Kim, I., Paik, C. H., Choyke, P. L., and Kobayashi, H. (2014) Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor Mol. Oncol. 8, 620-32 10.1016/j.molonc.2014.01.006
158. Nakajima, T., Sano, K., Mitsunaga, M., Choyke, P. L., and Kobayashi, H. (2012) Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging Cancer Res. 72, 4622-8 10.1158/0008-5472.CAN-12-1298
159. Shirasu, N., Yamada, H., Shibaguchi, H., and Kuroki, M. (2014) Potent and specific antitumor effect of CEA-targeted photoimmunotherapy Int. J. Cancer 135, 2697-710 10.1002/ijc.28907
160. Kerr, J. F. (1971) Shrinkage necrosis: a distinct mode of cellular death J. Pathol. 105, 13-20 10.1002/path.1711050103
161. Willingham, M. C. (1999) Cytochemical methods for the detection of apoptosis J. Histochem. Cytochem. 47, 1101-10 10.1177/002215549904700901
162. Ziegler, U. and Groscurth, P. (2004) Morphological features of cell death News Physiol. Sci. 19, 124-8 10.1152/nips.01519.2004
163. Sano, K., Nakajima, T., Choyke, P. L., and Kobayashi, H. (2013) Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors ACS Nano 7, 717-24 10.1021/nn305011p
164. Hanaoka, H., Nakajima, T., Sato, K., Watanabe, R., Phung, Y., Gao, W., Harada, T., Kim, I., Paik, C. H., and Choyke, P. L. et al. 2015, Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel Nanomedicine (London, U. K.) 10, 1139-47 10.2217/nnm.14.194
165. Nagaya, T., Nakamura, Y., Sato, K., Harada, T., Choyke, P. L., and Kobayashi, H. (2016) Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT) J. Controlled Release 232, 1-8 10.1016/j.jconrel.2016.04.003
166. Kobayashi, H. and Choyke, P. L. (2016) Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy Nanoscale 8, 12504-9 10.1039/C5NR05552K